Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular Analysis for Therapy Choice (MATCH)

Trial Profile

Molecular Analysis for Therapy Choice (MATCH)

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2019

At a glance

  • Drugs Adavosertib (Primary) ; Afatinib (Primary) ; AZD 4547 (Primary) ; Binimetinib (Primary) ; Capivasertib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dasatinib (Primary) ; Defactinib (Primary) ; GSK 2636771 (Primary) ; Larotrectinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sapanisertib (Primary) ; Sunitinib (Primary) ; Taselisib (Primary) ; Trametinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Vismodegib (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Glioblastoma; Lymphoma; Multiple myeloma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms MATCH; NCI-MATCH
  • Most Recent Events

    • 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 24 Sep 2018 According to a NeoGenomics media release, the company announced today that it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine cancer treatment clinical trial.
    • 28 Aug 2018 According to a OPKO Health media release, the BioReference Laboratories ( a subsidiary of OPKO Health ) has signed an agreement with NCI and ECOG-ACRIN to participate in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top